In vivo engineering of B cells for the secretion of HIV broadly neutralizing antibodies
Active Project Grant Awarded Last action
- Award ID
- R01AI167003
- Recipient
-
Scripps Research Institute UEI PHZJFZ32NKH4
- Awarding agency
-
National Institute of Allergy and Infectious Diseases
National Institutes of Health, Department of Health and Human Services
- Obligated
- $3,535,836
Award facts
- Assistance listing
- 93.855 Allergy and Infectious Diseases Research
- Completion date 99% complete
- Place of performance
- La Jolla, CA 92037, USA
Award details come from USAspending.gov.
Description
- Abstract
- We have developed a novel gene therapeutic approach to achieve an HIV functional cure, wherein broadly neutralizing antibody (BNAB) genes are targeted to the endogenous heavy chain locus in B cells for expression as functional antigen-receptors (BCRS). This takes advantage of the precision of gene editing conferred by crispr-CAS9 reagents and homology-directed gene editing. We have shown that these broadly neutralizing BCRS respond to HIV ENV immunogens by signaling clonal expansion and germinal center maturation of the engineered cells and thereby generate durable, isotype-switched memory BNAB responses that could be deployed for long-term control of HIV. Given these features of B cell biology, which are preserved by our gene editing approach, we hypothesize that sufficient neutralizing antibody titers in serum could be generated from very few engineered B cells, including the levels achieved by in vivo delivery of genome-editing reagents directly to the target cells. In support of this approach, we have now shown that high-titer BNAB responses can be elicited in mice by vaccination with HIV-ENV immunogens when the animals are injected with a transcriptionally-targeted dual-AAV vector system carrying the BNAB editing reagents. Unlike injection of recombinant bnabs, or AAV- vectored delivery of BNAB-IGG expression cassettes to liver or muscle for long-term secretion from viral episomes, bnabs generated from in vivo gene-edited B cells in response to vaccination are expected to have the following advantages: 1) be boostable, as needed, in response to viral antigen, 2) express bnabs as all effector isotypes to expand antiviral immunity, 3) affinity-mature or evolve the BNAB response to keep-pace with a rapidly evolving virus, and 4) be better tolerated by the immune system. To further develop this approach, we have assembled a team that brings together expertise in B cell engineering, vector development, HIV vaccine design, and animal models to further develop this in vivo delivery approach to specifically and efficiently engineer B cells in vivo and to evaluate this approach as an in vivo HIV cure.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Amendment | $145,896 | |
| Amendment | $571,808 | |
| Amendment | $700,174 | |
| Amendment | $0 | |
| Amendment | $73,362 | |
| Amendment | $660,269 | |
| Amendment | $738,581 | |
| Original award | $645,746 |
Subawards
| Subrecipient | Amount | Awarded |
|---|---|---|
| Tel Aviv University | $145,896 | |
| University Of Southern California | $203,177 | |
| University Of Southern California | $202,783 | |
| Tel Aviv University | $138,331 | |
| University Of Southern California | $212,954 | |
| University Of Wisconsin System | $137,193 | |
| Tel Aviv University | $143,196 | |
| University Of Southern California | $213,807 | |
| Tel Aviv University | $143,196 | |
| Tel Aviv University | $143,196 | |
| University Of Southern California | $213,041 |
Show all 11
Quick answers
Who received award R01AI167003?
R01AI167003 was awarded to Scripps Research Institute by National Institute of Allergy and Infectious Diseases (National Institutes of Health) on December 2, 2021.
How much is award R01AI167003 worth?
$3,535,836 has been obligated on R01AI167003.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award